NewAmsterdam Pharma Company N.V. (NAMS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
NewAmsterdam Pharma Company N.V. (NAMS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
NAMS - NewAmsterdam Pharma Company N.V.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$46.00
DETAILS
HIGH:
$55.00
LOW:
$37.00
MEDIAN:
$46.00
CONSENSUS:
$46.00
UPSIDE:
29.80%
Stock News
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May
NAARDEN, the Netherlands and MIAMI, May 11, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:
NewAmsterdam Pharma Company N.V. (NAMS) Discusses Clinical Development Update and Interim Analysis Plans for PREVAIL Trial Transcript
NewAmsterdam Pharma Company N.V. (NAMS) Discusses Clinical Development Update and Interim Analysis Plans for PREVAIL Trial Transcript
NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends
NewAmsterdam Pharma NASDAQ: NAMS said it plans to conduct an interim analysis of its ongoing PREVAIL cardiovascular outcomes trial (CVOT) for obicetrapib in the fourth quarter of 2026, citing what executives described as encouraging trends in two-year blinded data and a lower-than-anticipated major adverse cardiovascular event (MACE) rate from year one to year two.
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates
NewAmsterdam Pharma Company N.V. (NAMS) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.46.
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
– Decisions on regulatory approval from EMA, UK, and Switzerland for obicetrapib and obicetrapib/ezetimibe fixed - dose combination expected in 2H26, and based on the outcomes, with potential launches by Menarini in 4Q26 in Germany and the UK – – PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027 – – Completed enrollment in REMBRANDT; Topline data from RUBENS Phase 3 expected by year-end 2026 – – Presented new analyses of Phase 3 BROOKLYN and BROADWAY studies at the American College of Cardiology Annual Scientific Session (ACC) and simultaneously published in the American Journal of Preventative Cardiology– – $707.3 million in cash, cash equivalents and marketable securities at March 31, 2026 – – Management to host PREVAIL update call today at 8:00 AM ET – NAARDEN, the Netherlands and MIAMI, May 07, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced financial results for the quarter ended March 31, 2026 and provided a corporate update.
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, the Netherlands and MIAMI, May 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam's Board of Directors approved the grant of inducement share options covering an aggregate of 50,400 of NewAmsterdam's ordinary shares to five non-executive new hires. The share options were granted as an inducement material to the employees' acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).
NewAmsterdam Pharma: Cholesterol-Lowering Player Is A Risk-On Buy Today
NewAmsterdam Pharma is advancing obicetrapib, an oral CETP inhibitor, targeting unmet LDL-C lowering needs in cardiovascular disease patients. Obicetrapib met primary and secondary endpoints in three Phase 3 trials, with significant LDL-C reductions and favorable safety, supporting regulatory filings in Europe and the US. NAMS anticipates regulatory decisions in Europe in H2 2026, with US NDA likely post-PREVAIL CVOT data; commercial preparations and partnerships are underway.
NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference
NAARDEN, the Netherlands and MIAMI, April 08, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a virtual fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 11:45 a.m.
Financial Comparison: NewAmsterdam Pharma (NASDAQ:NAMS) and Shineco (NASDAQ:SISI)
NewAmsterdam Pharma (NASDAQ: NAMS - Get Free Report) and Shineco (NASDAQ: SISI - Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership. Institutional and Insider Ownership 89.9% of NewAmsterdam Pharma shares
Aberdeen Group plc Has $25.59 Million Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMS
Aberdeen Group plc grew its holdings in NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) by 10.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 729,484 shares of the company's stock after purchasing an additional 67,538 shares during the period. Aberdeen Group plc owned
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, the Netherlands and MIAMI, April 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam's Board of Directors approved the grant of inducement share options covering an aggregate of 15,000 of NewAmsterdam's ordinary shares to two non-executive new hires. The share options were granted as an inducement material to the employees acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).
NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session
NAARDEN, The Netherlands and MIAMI, March 23, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data highlighting the potential for obicetrapib as a novel, oral, low-dose therapy for hypercholesterolemia, at the at the American College of Cardiology Annual Scientific Session (ACC.26), taking place on March 28-30 in New Orleans, Louisiana.
NewAmsterdam Pharma (NASDAQ:NAMS) Insider Johannes Jacob Piete Kastelein Sells 101,409 Shares
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS - Get Free Report) insider Johannes Jacob Piete Kastelein sold 101,409 shares of the business's stock in a transaction on Monday, March 9th. The stock was sold at an average price of $30.29, for a total transaction of $3,071,678.61. Following the sale, the insider owned 69,302 shares in the company,
NewAmsterdam Pharma (NASDAQ:NAMS) Insider Johannes Jacob Piete Kastelein Sells 104,467 Shares
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS - Get Free Report) insider Johannes Jacob Piete Kastelein sold 104,467 shares of the stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $30.30, for a total value of $3,165,350.10. Following the sale, the insider owned 69,302 shares of the company's stock,
NewAmsterdam Pharma (NASDAQ:NAMS) Insider Johannes Jacob Piete Kastelein Sells 94,124 Shares of Stock
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS - Get Free Report) insider Johannes Jacob Piete Kastelein sold 94,124 shares of the company's stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $30.32, for a total transaction of $2,853,839.68. Following the transaction, the insider owned 69,302 shares in
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, the Netherlands and MIAMI, March 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam's Board of Directors approved the grant of inducement share options covering an aggregate of 10,000 of NewAmsterdam's ordinary shares to two non-executive new hires. The share options were granted as an inducement material to the employees' acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).
Michael Davidson Sells 183,332 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS - Get Free Report) CEO Michael Davidson sold 183,332 shares of the business's stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $33.71, for a total value of $6,180,121.72. Following the transaction, the chief executive officer directly owned 174,144 shares
Johannes Jacob Piete Kastelein Sells 45,481 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS - Get Free Report) insider Johannes Jacob Piete Kastelein sold 45,481 shares of the business's stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $35.31, for a total value of $1,605,934.11. Following the transaction, the insider directly owned 53,500 shares of the
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
NAARDEN, the Netherlands and MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:
Price Targets
NewAmsterdam Pharma price target raised to $45 from $41 at Guggenheim
$45.00
(was $35.76)
Guggenheim
NewAmsterdam Pharma price target raised to $47 from $44 at RBC Capital
$47.00
(was $32.41)
RBC Capital
NewAmsterdam Pharma Co NV (NAMS) PT Raised to $55 at Leerink Partners
$55.00
(was $33.48)
Roanna Ruiz
·
Leerink Partners
NewAmsterdam Pharma price target raised to $37 from $30 at Goldman Sachs
$37.00
(was $39.61)
Goldman Sachs
NewAmsterdam Pharma assumed with a Buy at H.C. Wainwright
$52.00
(was $36.40)
Joseph Pantginis
·
H.C. Wainwright
NewAmsterdam Pharma initiated with an Overweight at Wells Fargo
$45.00
(was $24.70)
Wells Fargo
NewAmsterdam Pharma price target raised to $41 from $35 at Guggenheim
$41.00
(was $20.27)
UBS
NewAmsterdam Pharma initiated with a Buy at H.C. Wainwright
$48.00
(was $25.60)
Ed Arce
·
H.C. Wainwright
NewAmsterdam Pharma Co NV (NAMS) PT Raised to $45 at Leerink Partners
$45.00
(was $20.01)
Roanna Ruiz
·
Leerink Partners
Piper Sandler Reiterates Overweight Rating on NewAmsterdam Pharma Co NV (NAMS)
$37.00
(was $15.95)
Yasmeen Rahimi
·
Piper Sandler
NewAmsterdam Pharma initiated with a Buy at Needham
$36.00
(was $16.77)
Serge Belanger
·
Needham